At a glance
ClinicalIndex Comparison RecordN/ACompleted· 728 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice
In Brief
An observational study evaluating Infliximab for Rheumatoid Arthritis. Completed, enrolled 728 participants.
Detailed Summary
This 14-week non-interventional study will observe patients with rheumatoid arthritis (RA) who are being treated with infliximab for the first time, in order to learn about their disease characteristics. Patients in this study will be treated for RA with infliximab and in a usual manner as decided by their physician.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedJun 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedJun 26, 2008
Enrollment StartDec 1, 2005
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.0 years ago
Interventions
Infliximabbiological
Infliximab used in line with current clinical practice and local guidelines.